Kamada Ltd. KMDA

Company Overview

Kamada Ltd. is an Israel-based biopharmaceutical company focused on the development, manufacturing, and commercialization of specialty plasma-derived therapeutics. The company operates primarily in the biopharmaceutical and specialty therapeutics industries, with a concentration on immune globulin-based products, plasma collection, and specialty biologics used for rare and serious conditions. Kamada’s revenue is generated through proprietary product sales, distribution agreements, plasma collection activities, and contract manufacturing services.

The company’s core business lines include specialty plasma-derived therapeutics such as Glassia, an intravenous Alpha-1 Antitrypsin (AAT) therapy for Alpha-1 Antitrypsin Deficiency, as well as rabies immune globulin and other immunoglobulin products. Kamada also operates plasma collection centers in the United States and distributes several specialty products through strategic partnerships. Founded in 1990 in Israel, Kamada evolved from a plasma-derived therapeutics developer into a vertically integrated biopharmaceutical company with commercial operations across multiple international markets. Its strategic positioning is supported by specialized plasma expertise, regulatory-approved manufacturing capabilities, and long-term partnerships with larger pharmaceutical companies.